• DOI:10.1111/cge.12344
• Corpus ID: 42342267

Founder mutation for Huntington disease in Caucasus Jews

@article{Melamed2015FounderMF,
  title={Founder mutation for Huntington disease in Caucasus Jews},
  author={Oleg Melamed and Doron M Behar and Chen Bram and Nurit Magal and Eran Pras and Haike Reznik‐Wolf and Zvi U. Borochowitz and Bella Davidov and R. Mor-cohen and Hagit N Baris},
  journal={Clinical Genetics},
  year={2015},
  volume={87}
}

• O. Melamed, D. Behar, +7 authors H. Baris
• Published 1 February 2015
• Medicine, Biology
• Clinical Genetics

Huntington disease (HD), an autosomal dominant disorder involving HTT, is characterized by chorea, psychiatric illness and cognitive decline. Diagnosis and age of onset depend on the degree of expansion of the trinucleotide CAG repeat within the gene. The prevalence of HD is known for Europeans but has not been studied in the Israeli population. Between 2006 and 2011 we diagnosed in our adult genetics clinic ten HD probands, nine of whom were Caucasus Jews (CJ) (Azerbaijani), and one Ashkenazi Jewish. We performed haplotype analysis to look for evidence of a founder mutation, and found that of the nine CJ, eight shared the same haplotype that was compatible with the A1 haplogroup. We calculated the coalescence age of the mutation to be between 80 and 150 years. Ninety percent of our HD patients are CJ, as are 27% of the HD patients in Israel, although the CJ comprise only 1.4% of the Israeli population. Our findings suggest a higher prevalence of HD among CJ compared to the general Israeli population and are consistent with a recent founder mutation. We recommend a higher degree of suspicion for HD in CJ with subtle clinical findings.